

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Cavaleri et al. :  
APPLICATION NO.: 10/829,068 : Examiner: E. Peseelev  
FILING DATE: 20 April 2004 : Group Art Unit: 1623  
TITLE: Stable Compositions of Dalbavancin :

Via EFS

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant(s) hereby bring to the Examiner's attention the documents cited in the attached PTO-FB-A820, copies of which are enclosed (other than cited U.S. patent documents).


The Examiner is respectfully requested to consider the cited documents in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a) and to indicate such by returning a signed and initialed copy of the PTO-FB-A820 and listing the documents in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The required fee under 37 C.F.R. § 1.17(p) is being paid herewith via EFS. The Commissioner is authorized to charge any fees, which may be required, or credit any overpayment, to Account No. 16-1445.

Should there be any questions, the Examiner is invited to contact the undersigned.

Respectfully submitted,

Date: 1 May 2007

  
Frank W. Forman  
Attorney for Applicant(s)  
Reg. No. 42,547

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-5669  
[frank.w.forman@pfizer.com](mailto:frank.w.forman@pfizer.com)